Physician profile
Jules Monier
NPI 1427049725
$3,399.55
in general payments reported to CMS, 2019-2025
34 companies · $24.56 in 2025
The $24.56 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $145 · 2021: $485 · 2022: $1,726 · 2023: $631 · 2024: $63.80 · 2025: $24.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $719.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $1,125.01 | 2022 | |
| Abbvie INC. | $369.19 | 2019-2023 | |
| Coopersurgical, INC. | $153.75 | 2019-2021 | |
| Pfizer INC. | $146.33 | 2019-2023 | |
| Hologic Sales and Service, LLC | $143.67 | 2022-2025 | Aptima, Thinprep 2000 Processor |
| Gynesonics, INC. | $133.16 | 2022 | |
| Innovation Technologies INC | $131.50 | 2022-2023 | Irrisept |
| Ascend Therapeutics US, LLC | $120.82 | 2023 | |
| Organon LLC | $104.02 | 2021-2023 | Nexplanon |
| Applied Medical Resources Corporation | $86.01 | 2021 | |
| Merck Sharp & Dohme LLC | $77.90 | 2019-2021 | |
| Boston Scientific Corporation | $67.49 | 2019-2021 | |
| Daiichi Sankyo INC. | $59.45 | 2019-2021 | |
| Astellas Pharma US INC | $54.63 | 2023 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $54.19 | 2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $47.71 | 2022 | |
| Myovant Sciences INC. | $46.14 | 2022 | |
| Millicent US INC | $43.21 | 2022-2023 | Intrarosa |
| Pacira Pharmaceuticals Incorporated | $41.42 | 2019-2023 | Exparel |
| Sumitomo Pharma America, INC. | $41.31 | 2023 | Myfembree |
| Avanos Medical | $41.28 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $39.71 | 2023 | Seglentis |
| Therapeuticsmd, INC. | $39.27 | 2019-2022 | |
| Coloplast Corp | $36.40 | 2021 | |
| Duchesnay USA Incorporated | $30.88 | 2019 | |
| Mylan Pharmaceuticals INC. | $28.94 | 2019-2021 | |
| Avion Pharmaceuticals | $25.92 | 2021 | |
| Integra Lifesciences Corporation | $21.05 | 2022 | |
| Davol INC. | $20.49 | 2021 | |
| Baxter Healthcare | $15.54 | 2023 | Tisseel |
| Becton, Dickinson and Company | $14.66 | 2022 | |
| Acessa Health INC. | $14.22 | 2021 | |
| Agile Therapeutics, INC. | $12.60 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jules Monier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.